Leuprolide acetate: Pharmaceutical use and delivery potentials

Expert Opinion on Drug Delivery

Volumn 9, Issue 3, 2012, Pages 343-354

  Teutonico, Donato ^a,b,c   Montanari, Silvia ^a,b   Ponchel, Gilles ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b IPSIT   (France)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Drug delivery; Leuprolide acetate; LH RH agonist; Protein delivery; Routes of administration

Indexed keywords

CHITOSAN; LEUPRORELIN; LIPOSOME; NAFARELIN;

AREA UNDER THE CURVE; BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; REVIEW;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; ENDOMETRIOSIS; FEMALE; GENITAL DISEASES, FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS, SUBCUTANEOUS; LEUPROLIDE; MALE; PROSTATIC NEOPLASMS; PUBERTY, PRECOCIOUS; RECEPTORS, LHRH;

EID: 84857583598     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.662484     Document Type: Review

References (95)

1. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005;4:298-306 (Pubitemid 41130943)
2. Kalluri H, Banga AK. Transdermal delivery of proteins. AAPS PharmSciTech 2011;12:431-41
3. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 2006;11:905-10 (Pubitemid 44403178)
4. Scheuch G, Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol 2007;58:615-25 (Pubitemid 351346710)
5. Tranchand B. Guide pratique de pharmacocinétique clinique en oncologie, Editions Frison-Roche, 1997
6. Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84 (Pubitemid 39078560)
7. Wilson AC, Meethal SV, Bowen RL, et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Drug Eval 2007;16:1851-63 (Pubitemid 350187397)
8. Sanofi-Aventis, ELIGARD 7,5 mg product information. 2009
9. Chodak G. A critical review of maximal androgen blockade for advanced prostate cancer. Rev Urol 2004;6:18-23
10. Kostanski JW, Dani BA, Schrier B, et al. Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats. Pharm Res 2000;17:445-50 (Pubitemid 30395300)
11. Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53 (Pubitemid 32112845)
12. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998;4:527-34 (Pubitemid 28193549)
13. Emons G, Ortmann O, Schulz KD, et al. Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab 1997;8:355-62 (Pubitemid 28034420)
14. Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002;109:E30
15. Covens A, Thomas G, Shaw P, et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 1997;64:126-9 (Pubitemid 27026969)
16. Kavanagh JJ, Roberts W, Townsend P, et al. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989;7:115-18 (Pubitemid 19089089)
17. Webber KM, Casadesus G, Bowen RL, et al. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 2007;7:300-3
18. Webber KM, Perry G, Smith MA, et al. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res 2007;5:177-83 (Pubitemid 351303232)
19. Stevenson CL, Leonard JJ, Hall SC. Effect of peptide concentration and temperature on leuprolide stability in dimethyl sulfoxide. Int J Pharm 1999;191:115-29 (Pubitemid 29516476)
20. Wright JC, Tao Leonard S, Stevenson CL, et al. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Control Release 2001;75:1-10 (Pubitemid 32635192)
21. Viadur. Available from: http://www. pharma.bayer.com 2010
22. MicroCHIPS, Inc. Available from: http://www.mchips.com 2010
23. Li Y, Shawgo RS, Tyler B, et al. In vivo release from a drug delivery MEMS device. J Control Release 2004;100:211-19 (Pubitemid 39491273)
24. Maloney JM, Uhland SA, Polito BF, et al. Electrothermally activated microchips for implantable drug delivery and biosensing. J Control Release 2005;109:244-55 (Pubitemid 41737268)
25. Prescott JH, Lipka S, Baldwin S, et al. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotechnol 2006;24:437-8
26. Prescott JH, Krieger TJ, Lipka S, et al. Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multi-reservoir array. Pharm Res 2007;24:1252-61 (Pubitemid 46870590)
27. Luan X, Bodmeier R. Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly(lactide-coglycolide) microparticles. Eur J Pharm Biopharm 2006;63:205-14 (Pubitemid 43776217)
28. Ravivarapu HB, Burton K, DeLuca PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm 2000;50:263-70
29. Packhaeuser CB, Schnieders J, Oster CG, et al. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004;58:445-55 (Pubitemid 39037247)
30. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release 2002;80:9-28 (Pubitemid 34273745)
31. Singh S, Singh J. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits. Int J Pharm 2007;328:42-8 (Pubitemid 44827559)
32. QLT, Inc. Available from: http://www. qltinc.com 2010
33. Luan X, Bodmeier R. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters. Eur J Pharm Sci 2006;27:143-9 (Pubitemid 41831249)
34. Kranz H, Brazeau GA, Napaporn J, et al. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm 2001;212:11-18 (Pubitemid 32121946)
35. Dong WY, Korber M, Lopez Esguerra V, et al. Stability of poly(D,L-lactide-coglycolide) and leuprolide acetate in in-situ forming drug delivery systems. J Control Release 2006;115:158-67 (Pubitemid 44537494)
36. Pacira Pharmaceuticals. Available from: http://www.pacira.com 2010
37. Ye Q, Asherman J, Stevenson M, et al. DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. J Control Release 2000;64:155-66 (Pubitemid 30035316)
38. Slager J, Domb AJ. Hetero-stereocomplexes of D-poly(lactic acid) and the LHRH analogue leuprolide. Application in controlled release. Eur J Pharm Biopharm 2004;58:461-9 (Pubitemid 39297092)
39. Arulsudar N, Subramanian N, Mishra P, et al. Preparation, characterization, and biodistribution study of technetium-99 m -labeled leuprolide acetate-loaded liposomes in Ehrlich ascites tumor-bearing mice. AAPS PharmSci 2004;6:E5
40. Singh P, Maibach HI. Iontophoresis: an alternative to the use of carriers in cutaneous drug delivery. Adv Drug Deliv Rev 1996;18:379-94 (Pubitemid 26063310)
41. Merino V, Kalia YN, Guy RH. Transdermal therapy and diagnosis by iontophoresis. Trends Biotechnol 1997;15:288-90 (Pubitemid 27330622)
42. Schuetz YB, Carrupt PA, Naik A, et al. Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis. Eur J Pharm Sci 2006;29:53-9 (Pubitemid 44294860)
43. Kochhar C, Imanidis G. In vitro transdermal iontophoretic delivery of leuprolide under constant current application. J Control Release 2004;98:25-35 (Pubitemid 38881604)
44. Kochhar C, Imanidis G. In vitro transdermal iontophoretic delivery of leuprolide-mechanisms under constant voltage application. J Pharm Sci 2003;92:84-96 (Pubitemid 36042300)
45. Delgado-Charro MB, Guy RH. Iontophoretic delivery of nafarelin across the skin. Int J Pharm 1995;117:165-72
46. Meyer BR, Kreis W, Eschbach J, et al. Transdermal versus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect. Clin Pharmacol Ther 1990;48:340-5 (Pubitemid 20362266)
47. Zheng Y, FuLu MY, Qiu Y, et al. Enzymatic degradation of leuprolide in rat intestinal mucosal homogenates. Pharm Dev Technol 1999;4:539-44 (Pubitemid 29536074)
48. Zheng Y, Qiu Y, Lu MF, et al. Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. Int J Pharm 1999;185:83-92 (Pubitemid 29333099)
49. Zheng JY, Fulu MY. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion. Int J Pharm 2006;307:209-15 (Pubitemid 41820416)
50. Guo J, Ping Q, Jiang G, et al. Chitosan-coated liposomes: characterization and interaction with leuprolide. Int J Pharm 2003;260:167-73 (Pubitemid 36773915)
51. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev 2001;47:83-97 (Pubitemid 32209234)
52. Iqbal J, Shahnaz G, Perera G, et al. Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. Eur J Pharm Biopharm 2012;80:95-102
53. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev 2005;57:1569-82 (Pubitemid 41443470)
54. Guo J, Ping Q, Jiang G, et al. Transport of leuprolide across rat intestine, rabbit intestine and Caco-2 cell monolayer. Int J Pharm 2004;278:415-22 (Pubitemid 38759513)
55. Iqbal J, Vigl C, Moser G, et al. Development and in vivo evaluation of a new oral nanoparticulate dosage form for leuprolide based on polyacrylic acid. Drug Deliv 2011;18:432-40
56. Soligenix. Available from: http://www. soligenix.com 2010
57. Teutonico D, Ponchel G. Patches for improving gastrointestinal absorption: an overview. Drug Discov Today 2011;16:991-7
58. Teutonico D, Montanari S, Ponchel G. Concentration and surface of absorption: concepts and applications to gastrointestinal patches delivery. Int J Pharm 2011;413:87-92
59. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech 2005;6:E482-6
60. Adjei A, Hui J, Finley R, et al. Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and preclinical issues. Int J Pharm 1994;107:57-66 (Pubitemid 24150378)
61. Adjei A, Sundberg D, Miller J, et al. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res 1992;9:244-9
62. Suzuki Y, Makino Y. Mucosal drug delivery using cellulose derivatives as a functional polymer. J Control Release 1999;62:101-7 (Pubitemid 29486488)
63. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004;26:137-42 (Pubitemid 39012580)
64. Alcock R, Blair JA, O'Mahony DJ, et al. Modifying the release of leuprolide from spray dried OED microparticles. J Control Release 2002;82:429-40 (Pubitemid 34880196)
65. Qiu Y, Johnson HW, Reiland TL, et al. Sublingual absorption of leuprolide: comparison between human and animal models. Int J Pharm 1999;179:27-36 (Pubitemid 29115057)
66. Lupron. Available from: http://www. lupron.com 2010
67. Eligard. Available from: http://www. eligard.com 2010
68. Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 2007;13:241-5 (Pubitemid 46121875)
69. Agarwal N, Fletcher D, Ward J. Obesity and treatment of prostate cancer: what is the right dose of lupron depot? Clin Cancer Res 2007;13:4027 (Pubitemid 47037613)
70. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. European Urology 2008;53(1):68-80 (Pubitemid 350166735)
71. Petrus M, Vigouroux A, Dumas C, et al. L'allergie a la triptoreline: revue et commentaires a propos d'un cas pediatrique. Revue Francaise d'Allergologie Et d'Immunologie Clinique 2007;47:89-91 (Pubitemid 46441675)
72. Raj SG, Karadsheh AJ, Guillot RJ, et al. Case report: systemic hypersensitivity reaction to goserelin acetate. Am J Med Sci 1996;312:187-90 (Pubitemid 26328350)
73. Lam C, Tjon J, Hamilton J, et al. Recurrent anaphylaxis associated with gonadotropin-releasing hormone analogs: case report and review of the literature. Pharmacotherapy 2006;26:1811-15 (Pubitemid 44885336)
74. Taylor JD. Anaphylactic reaction to LHRH analogue, leuprorelin. Med J Aust 1994;161:455 (Pubitemid 24296669)
75. TAP Pharmaceuticals, Lupron depot 7.5 mg prescribing infrmations. 2010
76. Lucrin. Available from: http://www.lucrin.nl 2010
77. Takeda. Available from: http://www. takeda.com 2010
78. Abbott. Available from: http://www. abbott.com 2010
79. Eriochem. Available from: http://www. eriochem.com 2010
80. Sanofi-Aventis, Suprefact (Buserelin acetate) - prescribing informations. 2010
81. AstraZaneca, Zoladex (goserelin) product prescribing informations. 2010
82. AstraZeneca. Available from: http://www. astrazaneca.com 2010
83. Endo Pharmaceuticals, Vantas (histrelin implant) prescribing informations. 2010
84. Endo Pharmaceuticals. Available from: http://www.endo.com 2010
85. Pfizer, Synarel (nafarelin acetate) nasal solution prescribing information. 2005
86. Pfizer. Available from: http://www.pfizer. com 2010
87. Ipsen, Diphereline S.R. 11.25 mg prescribing informations. 2004
88. Ferring Pharmaceuticals. Available from: http://www.ferring.com 2010
89. Watson. Available from: http://www. watson.com 2010
90. Sanofi Aventis. Available from: Press release 26 Jenuary 2005 2010
91. Consumer Medicine Information. Available from: http://www.betterhealth. vic.gov.au/ Lucrin Injection 2010
92. Enantone monograph. Available from: http://www.mims.com/; (n.d.)
93. Takeda Pharmaceuticals, Enantone 3.75/ 2 ml patient information leaflet. 2008
94. Bayer HealthCare Pharmaceuticals, Viadur (leuprolide acetate implant) prescribing informations. 2005
95. Kahn A, Gisselbrecht S. Histoire de la therapie ciblee en cancerologie, Amgen Oncologie - John Libbey Eurotext. 2007.